Literature DB >> 1968671

Heterocyclic antidepressant, monoamine oxidase inhibitor and neuroleptic withdrawal phenomena.

S C Dilsaver1.   

Abstract

1. The authors review the literature describing acute symptomatology produced by the gradual or abrupt withdrawal of heterocyclic antidepressants, monoamine oxidase inhibitors (MAOI) and neuroleptics. 2. Withdrawal of heterocyclic antidepressants and antipsychotic agents causes similar symptomatology. Symptoms produced by the discontinuation of these drugs include nausea, emesis, anorexia, diarrhea, rhinorrhea, diaphoresis, myalgias, paresthesias, anxiety, agitation, restlessness, and insomnia. 3. Psychotic relapse is often presaged by anxiety, agitation, restlessness, and insomnia. Prodromal symptoms are distinguished from the effects of neuroleptic withdrawal by a temporal relationship of the latter to reductions in the dosage or discontinuation of antipsychotic agents. 4. Withdrawal of MAOIs can result in severe anxiety, agitation, pressured speech, sleeplessness or drowsiness, hallucinations, delirium, and paranoid psychosis. 5. MAOI withdrawal phenomena resemble the symptoms produced by the discontinuation of chronically administered psychostimulants. 6. The capacity of MAOIs to exert amphetamine-like effects presynaptically and the propensity of somatic treatments for depression to subsensitize presynaptic receptors regulating the release of catecholamines provide a basis for the development of psychotic symptoms upon the withdrawal of MAOI. Evidence for this hypothesis is reviewed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1968671     DOI: 10.1016/0278-5846(90)90097-z

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  7 in total

Review 1.  Delirium: an important (but often unrecognized) clinical syndrome.

Authors:  Terry Rabinowitz
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

2.  Delirium, thrombocytopenia, insomnia, and mild liver damage associated with MAOI withdrawal.

Authors:  Alfredo Bellon; John H Coverdale
Journal:  Eur J Clin Pharmacol       Date:  2009-12       Impact factor: 2.953

3.  Tranylcypromine withdrawal: is it more common than we realize?

Authors:  N C Briggs
Journal:  J Psychiatry Neurosci       Date:  1994-11       Impact factor: 6.186

Review 4.  Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.

Authors:  K Black; C Shea; S Dursun; S Kutcher
Journal:  J Psychiatry Neurosci       Date:  2000-05       Impact factor: 6.186

Review 5.  Treatment of recurrent depression: a sequential psychotherapeutic and psychopharmacological approach.

Authors:  Giovanni A Fava; Chiara Ruini; Nicoletta Sonino
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

6.  Tranylcypromine withdrawal phenomena.

Authors:  M T Halle; S C Dilsaver
Journal:  J Psychiatry Neurosci       Date:  1993-01       Impact factor: 6.186

7.  Steps Following Attainment of Remission: Discontinuation of Antidepressant Therapy.

Authors:  Richard C. Shelton
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.